Long-term suppression of alkaline phosphatase levels and clinical remission with bisphosphonate therapy in two patients with Juvenile Paget disease
Abstract
Juvenile Paget disease (JPD) is an exceedingly rare, painful, and debilitating bone disease in children, most often caused by inactivating mutations in the TNFRSF11B gene that encodes the protein osteoprotegerin (OPG). Calcitonin and bisphosphonates, which are considered the mainstay of treatment in adult Paget disease, rarely cause sustained suppression of alkaline phosphatase (ALP) levels in children. We report two patients with JPD who experienced long-term suppression of ALP and clinical remission with bisphosphonate therapy. This is important data in the context of low- and middle-income countries, where access to recombinant OPG and denosumab is limited and often prohibitively expensive.
Fields of Study & Subjects
Bone health and treatments
Alkaline Phosphatase Research Studies
Bone health and osteoporosis research
Publication details
- Journal / source
- Journal of Pediatric Endocrinology and Diabetes
- Publisher
- Scientific Scholar
- Volume
- 6
- Pages
- 124–129
- Publication date
- 17 March 2026
- Language
- EN